Main Menu

NASDAQ (usa)	6715.56	-12.11	-0.18%
FTSE 100 (london)	7487.96	-5.12	-0.07%
DAX (german)	13465.51	235.94	1.78%
NIKKEI 225 (japan)	22420.08	408.47	1.86%
Hang - Seng (hong kong)	28594.06	348.52	1.23%

NIFTY - 50 (india)
Straits Times (singapore)	3391.61	17.53	0.52%
KOSPI (korea)	2556.47	33.04	1.31%
All Ordinaries (australia)	6005.30	28.90	0.48%
BOVESPA (brazil)	74092.76	-215.73	-0.29%

ABIOMED, Inc. (NASDAQ: ABMD)

ABMD Technical Analysis

As on 31st Oct 2017 ABMD Share Price closed @ 192.92 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 135.85 & Strong Buy for SHORT-TERM with Stoploss of 163.21 we also expect STOCK to react on Following IMPORTANT LEVELS.

ABMD Share Price

Open	180.12	Change	Price	%
High	193.95	1 Day	13.44	7.49
Low	180.12	1 Week	0.00	0.00
Close	192.92	1 Month	19.07	10.97
Volume	800004	1 Year	82.91	75.37
52 Week High 193.95 \| 52 Week Low 103.53

NASDAQ USA Most Active Stocks

YHOO	52.58	0.00%
FNFG	10.18	-0.20%
DELL	13.86	0.22%
RFMD	16.59	-2.07%
MU	44.31	6.39%
RIMM	13.03	0.39%
BBEP	0.12	0.00%
GTAT	0.44	0.00%
SUSQ	14.20	-0.77%
INTC	45.49	2.52%

More..

NASDAQ USA Top Gainers Stocks

LOCM	0.09	50.00%
SCHS	0.04	33.33%
BSDM	0.62	26.53%
SNTA	0.34	25.93%
HLIT	3.70	25.42%
OTT	2.39	25.13%
QNST	8.90	20.76%
VRTA	4.00	19.40%
SNSS	2.56	19.07%
GCFB	0.44	18.92%

More..

NASDAQ USA Top Losers Stocks

TXCC	0.01	-95.00%
GMETP	0.15	-76.92%
HCIIP	10.10	-67.52%
CRMB	0.27	-57.81%
KIOR	0.03	-57.14%
OSH	0.26	-49.02%
OSH	0.26	-49.02%
DVOX	0.05	-44.44%
PRXI	0.21	-43.24%
TRGT	0.96	-41.46%

More..

ABMD
Daily Charts

ABMD
Intraday Charts

Whats New @
Bazaartrend

ABMD
Free Analysis

ABMD Important Levels Intraday

SUPPORT	0.00
SUPPORT	0.00
RESISTANCE	205.74
RESISTANCE	200.46
SUPPORT	185.38
SUPPORT	180.10
SUPPORT	0.00
SUPPORT	0.00

ABMD Target for Month July

4th UP TARGET	249.09
3rd UP TARGET	231.08
2nd UP TARGET	219.94
1st UP TARGET	208.81
1st DOWN TARGET	177.03
2nd DOWN TARGET	165.9
3rd DOWN TARGET	154.76
4th DOWN TARGET	136.75

ABMD Weekly Target

4th UP TARGET	0.00
3rd UP TARGET	0.00
2nd UP TARGET	0.00
1st UP TARGET	0.00
1st DOWN TARGET	0.00
2nd DOWN TARGET	0.00
3rd DOWN TARGET	0.00
4th DOWN TARGET	0.00

ABMD Target for Year 2021

4th UP TARGET	0
3rd UP TARGET	0
2nd UP TARGET	0
1st UP TARGET	0
1st DOWN TARGET	0
2nd DOWN TARGET	0
3rd DOWN TARGET	0
4th DOWN TARGET	0

ABIOMED, Inc. ( NASDAQ USA Symbol : ABMD )
Sector : Healthcare And Other Stocks in Same Sector

ABAX
48.40 0.54 (1.13 %)
LT : Sell
ST : Buy

ABIO
1.21 0.01 (0.83 %)
LT : Strong Sell
ST : Sell

ABMD
192.92 13.44 (7.49 %)
LT : Strong Buy
ST : Strong Buy

ACAD
34.83 -0.35 (-0.99 %)
LT : Buy
ST : Sell

ACHC
31.36 0.03 (0.10 %)
LT : Strong Sell
ST : Strong Sell

ABMD Other Details

Segment	EQ
Market Capital	527299872.00
Sector	Healthcare
Industry	Medical Appliances & Equipment
Offical website	>

ABMD Address

22 Cherry Hill Drive
Danvers, MA 01923
United States
Phone: 978-646-1400
Fax: 978-777-8411

ABMD Latest News

Your Comments and Response on ABIOMED, Inc.

ABMD Business Profile

ABIOMED, Inc., incorporated on June 4, 1987, is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. In September 2012, the Company announced that its Impella CP product received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for partial circulatory support for up to six hours. In November 2012, the Company announced that the Impella RP received Investigational Device Exemption, or IDE, approval from the FDA for use in RECOVER RIGHT, a pivotal clinical study in the U.S. In December 2012, as part of the FDA's 515 Program Initiative, an FDA panel voted to recommend continuation of Class III status for temporary ventricular support devices within the non-roller type cardiopulmonary bypass blood pumps category, which includes the Company's Impella products. The Company Headquarters is at 22 Cherry Hill Drive, Danvers, Massachusetts 01923.

© 2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service